- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
The FDA granted IND clearance for Flare Therapeutics Inc.'s prioritized programs.
1 report, 1 independent
Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA granted IND clearance for Flare Therapeutics Inc.'s prioritized programs.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- FDA approved combination clearances for Elanco's Experior use on June 27, 2025.
- The FDA is a U.S. government agency, a basic descriptive fact about the regulator.
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.
- Discussion on the limits of pharmacotherapy and the role of FDA approvals.
- FDA approval coincided with Donald Trump's press conference on November 11, 2026.